2-(3-溴苯基)-噻唑-4-羧酸乙酯 | 786654-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(3-溴苯基)-噻唑-4-羧酸乙酯
• 英文名称: ethyl 2-(3-bromophenyl)-1,3-thiazole-4-carboxylate
• 英文别名: Ethyl 2-(3-bromophenyl)thiazole-4-carboxylate
• CAS: 786654-97-5
• 化学式: C₁₂H₁₀BrNO₂S
• mdl: MFCD06738338
• 分子量: 312.187
• InChiKey: DXNNRQNTJYNOPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(3-Bromo-phenyl)-thiazole-4-carboxylic acid ethyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(3-Bromo-phenyl)-thiazole-4-carboxylic acid ethyl ester
CAS number: 786654-97-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H10BrNO2S
Molecular weight: 312.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(3-溴苯基)-噻唑-4-羧酸乙酯 在 一水合肼 作用下， 生成 2-(3-bromophenyl)thiazole-4-carbonylhydrazine
  参考文献：
  名称：

  新恶二唑和噻唑类似物的合成，晶体结构，抗HIV和抗增殖活性

  摘要：

  合成了一系列2-金刚烷基-5-芳基噻唑基-1,3,4-恶二唑7a – x以及噻唑13和14。化合物7a中-升，13，和14在体外用的鉴定新的铅在MT-4细胞的化合物对人免疫缺陷病毒1型和人免疫缺陷病毒2型活性的活性的目的进行了测试。还测试了标题化合物对革兰氏阳性和革兰氏阴性细菌（金黄色葡萄球菌，沙门氏菌），各种分枝杆菌菌株（Fort分支杆菌和耻垢分枝杆菌（Mycobacterium smegmatis），酵母（白色念珠菌）和霉菌（Aspergillus fumigatus）。除了化合物13和14表现出抗人免疫缺陷病毒1活性（EC 50值为1.79和2.39μM，选择性指数分别为18和4）外，所有化合物均未显示出抗病毒或抗微生物活性。另一方面，化合物7a和7j对人CD4 +淋巴细胞（MT-4）显示出明显的细胞毒性。因此，评估了7a和7j对两种表现出IC的实体肿瘤衍生细胞系的抗增殖活性针对Hep-G2细胞系的50个值分别为8

  DOI：

  10.1007/s00044-016-1669-9
• 作为产物：
  描述：

  间溴苯甲腈 在 sodium hydrogen sulfide 、 magnesium(II) chloride hexahydrate 作用下， 以 乙醇 为溶剂， 生成 2-(3-溴苯基)-噻唑-4-羧酸乙酯
  参考文献：
  名称：

  新恶二唑和噻唑类似物的合成，晶体结构，抗HIV和抗增殖活性

  摘要：

  合成了一系列2-金刚烷基-5-芳基噻唑基-1,3,4-恶二唑7a – x以及噻唑13和14。化合物7a中-升，13，和14在体外用的鉴定新的铅在MT-4细胞的化合物对人免疫缺陷病毒1型和人免疫缺陷病毒2型活性的活性的目的进行了测试。还测试了标题化合物对革兰氏阳性和革兰氏阴性细菌（金黄色葡萄球菌，沙门氏菌），各种分枝杆菌菌株（Fort分支杆菌和耻垢分枝杆菌（Mycobacterium smegmatis），酵母（白色念珠菌）和霉菌（Aspergillus fumigatus）。除了化合物13和14表现出抗人免疫缺陷病毒1活性（EC 50值为1.79和2.39μM，选择性指数分别为18和4）外，所有化合物均未显示出抗病毒或抗微生物活性。另一方面，化合物7a和7j对人CD4 +淋巴细胞（MT-4）显示出明显的细胞毒性。因此，评估了7a和7j对两种表现出IC的实体肿瘤衍生细胞系的抗增殖活性针对Hep-G2细胞系的50个值分别为8

  DOI：

  10.1007/s00044-016-1669-9

文献信息

• [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015025025A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.

  这项发明涉及以下式的化合物（0）：其中Q，A1-A8，R4和R5分别具有如本文所述的含义。式（0）的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度活化的疾病和紊乱中是有用的。
• Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new oxadiazole and thiazole analogs
  作者：Mahmood-ul-Hassan Khan、Shahid Hameed、Tashfeen Akhtar、Najim A. Al-Masoudi、Wasfi A. Al-Masoudi、Peter G. Jones、Christophe Pannecouque

  DOI：10.1007/s00044-016-1669-9

  日期：2016.10

  A series of 2-adamantyl-5-arylthiazolyl-1,3,4-oxadiazoles 7a–x together with thiazoles 13 and 14 were synthesized. Compounds 7a–l, 13, and 14 were tested in vitro with the aim of identifying novel lead compounds active against human immunodeficiency virus type-1 and human immunodeficiency virus type-2 activity in MT-4 cells. Title compounds were also tested against representatives of Gram-positive

  合成了一系列2-金刚烷基-5-芳基噻唑基-1,3,4-恶二唑7a – x以及噻唑13和14。化合物7a中-升，13，和14在体外用的鉴定新的铅在MT-4细胞的化合物对人免疫缺陷病毒1型和人免疫缺陷病毒2型活性的活性的目的进行了测试。还测试了标题化合物对革兰氏阳性和革兰氏阴性细菌（金黄色葡萄球菌，沙门氏菌），各种分枝杆菌菌株（Fort分支杆菌和耻垢分枝杆菌（Mycobacterium smegmatis），酵母（白色念珠菌）和霉菌（Aspergillus fumigatus）。除了化合物13和14表现出抗人免疫缺陷病毒1活性（EC 50值为1.79和2.39μM，选择性指数分别为18和4）外，所有化合物均未显示出抗病毒或抗微生物活性。另一方面，化合物7a和7j对人CD4 +淋巴细胞（MT-4）显示出明显的细胞毒性。因此，评估了7a和7j对两种表现出IC的实体肿瘤衍生细胞系的抗增殖活性针对Hep-G2细胞系的50个值分别为8
• I₂/TBHP-Mediated tandem cyclization and oxidation reaction: Facile access to 2-substituted thiazoles and benzothiazoles
  作者：Li Liu、Chen Tan、Rong Fan、Zihan Wang、Hongguang Du、Kun Xu、Jiajing Tan

  DOI：10.1039/c8ob02826e

  日期：——

  readily available cysteine esters and 2-aminobenzenethiols as N and S sources. The reaction proceeds under an I2/TBHP system and involves a one-pot tandem cyclization and oxidation sequence. A diverse range of aldehydes is amenable for this transition-metal-free protocol, which provides an alternative method to rapidly access thiazole-containing molecules.

  利用容易获得的半胱氨酸酯和2-氨基苯硫醇作为N和S源，已经完成了2-取代的噻唑和苯并噻唑的有效合成。反应在I 2 / TBHP系统下进行，涉及一锅串联串联和氧化过程。这种无过渡金属的方案适用于多种醛类，这为快速访问含噻唑的分子提供了另一种方法。
• Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
  申请人：Chakravarty K. Prasun

  公开号：US20070060584A1

  公开（公告）日：2007-03-15

  Biaryl substituted thiazole, oxazole and imidazole compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treatment or prevention of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain comprise administering an effective amount of the present compounds, either alone, or in combination with one or more therapeutically active compounds.

  双芳基取代噻唑、噁唑和咪唑化合物是钠通道阻滞剂，可用于治疗疼痛。制药组合物包括有效量的本化合物，单独或与一个或多个治疗活性化合物组合，并含有药用载体。治疗或预防急性疼痛、慢性疼痛、内脏疼痛、炎症性疼痛和神经病理性疼痛的方法包括单独或与一个或多个治疗活性化合物组合，给予本化合物的有效量。
• NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS
  申请人：Euroscreen S.A.

  公开号：US20130023530A1

  公开（公告）日：2013-01-24

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及一种新型化合物I的使用作为治疗化合物。